Literature DB >> 10755323

Evidence for a role of chloroethylaziridine in the cytotoxicity of cyclophosphamide.

J L Flowers1, S M Ludeman, M P Gamcsik, O M Colvin, K L Shao, J H Boal, J B Springer, D J Adams.   

Abstract

UNLABELLED: A number of investigators have observed that the use of 4-hydroperoxycyclophosphamide (4-HC) in multiwell plate cytotoxicity assays can be associated with toxicity to cells in wells that contain no drug. Previous reports have implicated diffusion of 4-HC decomposition products, and acrolein in particular, as the active species.
PURPOSE: The purpose of this study was to elucidate the species responsible for the airborne cytotoxicity of 4-HC, and to devise ways to minimize such effects in chemosensitivity assays.
METHODS: To this end, analogues of 4-HC were synthesized to identify the contributions of individual cyclophosphamide metabolites to cytotoxicity. The analogues were then tested for activity against three human breast tumor cell lines (including a line resistant to 4-HC), and one non-small-cell lung carcinoma line. Cytotoxicity was evaluated by assays that quantitate cellular metabolism and nucleic acid content.
RESULTS: Didechloro-4-hydroperoxycyclophosphamide, a compound that generates acrolein and a nontoxic analogue of phosphoramide mustard, gave no cross-well toxicity. In contrast, a significant neighboring well effect was observed with phenylketophosphamide, a compound that generates phosphoramide mustard but not acrolein. Addition of authentic chloroethylaziridine reproduced the airborne toxicity patterns generated by 4-HC and phenylketophosphamide. Increasing the buffering capacity of the growth medium and sealing the microtiter plates prevented airborne cytotoxicity.
CONCLUSION: Since it is unlikely that phosphoramide mustard is volatile, these findings implicate chloroethylaziridine rather than acrolein as the volatile metabolite of 4-HC that is responsible for airborne cytotoxicity. The fact that chloroethylaziridine is generated in amounts sufficient to volatilize, diffuse across wells and cause cytotoxicity indicates that it is an important component in the overall cytotoxicity of 4-HC in vitro. Furthermore, these findings suggest that chloroethylaziridine may also contribute to the toxicity of cyclophosphamide in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755323     DOI: 10.1007/s002800050049

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

Review 1.  Roles of reactive oxygen species and antioxidants in ovarian toxicity.

Authors:  Patrick J Devine; Sally D Perreault; Ulrike Luderer
Journal:  Biol Reprod       Date:  2012-02-09       Impact factor: 4.285

2.  BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.

Authors:  David J Adams; William R Waud; Mansukh C Wani; Govindarajan Manikumar; James L Flowers; Timothy A Driscoll; Lee Roy Morgan
Journal:  Cancer Chemother Pharmacol       Date:  2010-06-22       Impact factor: 3.333

3.  Follicle-stimulating hormone and estradiol interact to stimulate glutathione synthesis in rat ovarian follicles and granulosa cells.

Authors:  Yvonne D Hoang; Brooke N Nakamura; Ulrike Luderer
Journal:  Biol Reprod       Date:  2009-06-10       Impact factor: 4.285

4.  Dissecting the impact of chemotherapy on the human hair follicle: a pragmatic in vitro assay for studying the pathogenesis and potential management of hair follicle dystrophy.

Authors:  Eniko Bodó; Desmond J Tobin; York Kamenisch; Tamás Bíró; Mark Berneburg; Wolfgang Funk; Ralf Paus
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

5.  Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals.

Authors:  Ryan J Hansen; Susan M Ludeman; Sari J Paikoff; Anthony E Pegg; M Eileen Dolan
Journal:  DNA Repair (Amst)       Date:  2007-05-07

6.  Ovarian xenobiotic biotransformation enzymes are altered during phosphoramide mustard-induced ovotoxicity.

Authors:  Jill A Madden; Aileen F Keating
Journal:  Toxicol Sci       Date:  2014-07-28       Impact factor: 4.849

7.  Involvement of a volatile metabolite during phosphoramide mustard-induced ovotoxicity.

Authors:  Jill A Madden; Patricia B Hoyer; Patrick J Devine; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2014-03-15       Impact factor: 4.219

8.  The role of proximal nephron in cyclophosphamide-induced water retention: preliminary data.

Authors:  Sua Kim; Chor Ho Jo; Joon-Sung Park; Ho Jae Han; Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2011-06-30

Review 9.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patients.

Authors:  N Pinto; E R Gamazon; N Antao; J Myers; A L Stark; A Konkashbaev; H K Im; S J Diskin; W B London; S M Ludeman; J M Maris; N J Cox; S L Cohn; M E Dolan
Journal:  Clin Pharmacol Ther       Date:  2014-02-18       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.